Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of dersimelagon in erythropoietic protoporphyria or X-linked protoporphyria
2019-004226-16Phase 3Completed
- Sponsor
- Mitsubishi Tanabe Pharma Development America
- Start
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) comparing Dersimelagon with Placebo (2 arms). Primary endpoint: Change from baseline in average daily sunlight exposure time to first prodromal symptom at Week 26. Started May 2020; status: completed.
02
Drugs
dersimelagon
03
Conditions
erythropoietic protoporphyria (EPP)X-linked protoporphyria (XLP)
Beyond the preview
Go deeper on 2019-004226-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004226-16.